

Special Issue

Methotrexate-Based Drug Delivery Systems: Advances in Disease Treatment

Message from the Guest Editor

Methotrexate (MTX) is a well-established drug for the treatment of a wide range of disease conditions such as cancer, psoriasis, and rheumatoid arthritis. Despite its well-established efficacy profile, MTX presents low permeability and solubility, which limits its absorption, being a constant target for pharmaceutical formulators engaging in new proposals of active pharmaceutical ingredient (API) solid-state variations and/or drug delivery system (DDS) platforms development, based on nanotechnology, smart polymers, controlled release, or alternative routes of administration to improve MTX bioavailability, reduce adverse effects, and maximize clinical efficacy, compared with conventional dosage forms.

This Special Issue aims to collect up-to-date formulation and targeting approaches for MTX, such as controlled release carriers, multiparticulate and nanotechnology-based systems, polymorphism, alternative routes of administration for the common goal of improving bioavailability, reduce adverse effects, and maximize clinical efficacy.

Guest Editor

Dr. Flávia Chiva Carvalho

Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas—UNIFAL, Alfenas, MG, Brazil

Deadline for manuscript submissions

20 April 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/203356

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).